Novanta Inc.
NOVTTechnologyNASDAQScientific & Technical Instruments · Last scanned Oct 26, 2026
Scan Results
Daily timeframeNovanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United. At a $5.32B market cap, Novanta Inc. ranks as a mid-cap company within technology. The company operates Automation Enabling Technologies and Medical Solutions segments.
Market Cap
$5.32B
Beta
1.73
P/E (TTM)
89.11
P/E (Fwd)
32.24
EPS (TTM)
$1.58
EPS (Fwd)
$4.37
ROE
5.1%
ROA
4.1%
Cash
$718.6M
Total Debt
$285.6M
Free CF
$118.4M
52W Change
7.2%
Annual Financials
Cash vs Debt
Where NOVT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NOVT finished 8.57% below its 150-day moving average ($143.84) and 7.02% below its 200-day moving average ($141.45). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NOVT overbought or oversold?
At the October 20, 2026 close, NOVT's RSI(14) was 40.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Novanta Inc. holds $718.6M in cash against $285.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $118.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 5.1% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $706.8M (2021) to $980.6M (2025), reflecting a 39% increase over the period.
Novanta Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. At over 50x earnings, NOVT carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NOVT.